These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23470476)

  • 1. [Utility of a microdose study for drug discovery and development].
    Yamaura Y
    Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):126-30. PubMed ID: 23470476
    [No Abstract]   [Full Text] [Related]  

  • 2. Concentration-controlled trials. What does the future hold?
    Johnston A; Holt DW
    Clin Pharmacokinet; 1995 Feb; 28(2):93-9. PubMed ID: 7736691
    [No Abstract]   [Full Text] [Related]  

  • 3. The utility of microdosing over the past 5 years.
    Lappin G; Garner RC
    Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel strategies for microdose studies using non-radiolabeled compounds.
    Maeda K; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdosing: current and the future.
    Lappin G
    Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
    Oosterhuis B
    Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
    [No Abstract]   [Full Text] [Related]  

  • 7. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
    Wagner CC; Langer O
    Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosing: the new pharmacokinetic paradigm?
    Zanni GR; Wick JY
    Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive designs for Phase I dose-finding studies.
    Zhou Y
    Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Rosenberger WF; Manukyan Z
    Stat Med; 2009 Dec; 28(30):3751-3; discussion 3759-60. PubMed ID: 19967756
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary on 'Designs of dose-escalation trials with quantitative responses'.
    Haines LM
    Stat Med; 2009 Dec; 28(30):3742-4; discussion 3759-60. PubMed ID: 19967751
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Atkinson AC
    Stat Med; 2009 Dec; 28(30):3739-41; discussion 3759-60. PubMed ID: 19967753
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictive Value of Microdose Pharmacokinetics.
    van Nuland M; Rosing H; Huitema ADR; Beijnen JH
    Clin Pharmacokinet; 2019 Oct; 58(10):1221-1236. PubMed ID: 31030372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human microdosing for the prediction of patient response.
    Henderson PT; Pan CX
    Bioanalysis; 2010 Mar; 2(3):373-6. PubMed ID: 21083245
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness analysis of microdose clinical trials in drug development.
    Yamane N; Igarashi A; Kusama M; Maeda K; Ikeda T; Sugiyama Y
    Drug Metab Pharmacokinet; 2013; 28(3):187-95. PubMed ID: 22971640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Senn S
    Stat Med; 2009 Dec; 28(30):3754-8; discussion 3759-60. PubMed ID: 19967754
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics and Dissemination of Phase 1 Trials Approved by a UK Regional Office in 2012.
    Odutayo A; Copsey B; Dutton S; Cook J; Hopewell S; Altman DG
    JAMA; 2017 May; 317(17):1799-1801. PubMed ID: 28464134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?
    Boyd RA; Lalonde RL
    Clin Pharmacol Ther; 2007 Jan; 81(1):24-6. PubMed ID: 17185993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.